Type 2 Diabetes

For many people with diabetes, continuous glucose monitoring has become an indispensable tool to accurately monitor real-time blood glucose levels and track glucose trends over time.

Testing the effectiveness of an innovative, clinic-level educational intervention to improve management of people with type 2 diabetes and CVD.

Risk for type 2 diabetes with use of menopausal hormone therapy varied by type of HT, according to a retrospective cohort study of women in South Korea published in Menopause.

Adults with type 2 diabetes who switched from liraglutide to semaglutide therapy had greater reductions in HbA1c and body weight at 26 weeks than those who switched to dulaglutide, according to study data from researchers in Japan.

Type 2 diabetes and atherosclerotic CVD risk varies considerably among Asian American subgroups and clinical trials assessing interventions must reflect the disparities within the Asian American population, researchers reported.

SEATTLE — Providers treating people with type 2 diabetes should take a complication-centric approach for determining first-line pharmacotherapy, according to a consensus statement.

A novel endoscopic procedure combined with semaglutide may eliminate the need for insulin while improving glycemic control and metabolic parameters among patients with type 2 diabetes.

Adults with type 2 diabetes and a high thyroid-stimulating hormone level are more likely to develop diabetic retinopathy, and low time in range further increases the risk for diabetic retinopathy, according to study data.

Adults with overweight or obesity and type 2 diabetes achieved a mean weight loss of more than 13% after taking either 10 mg or 15 mg of tirzepatide for 72 weeks, according to topline results from the SURMOUNT-2 trial.

The FDA granted clearance for a stand-alone, wearable insulin delivery pod for adults aged 18 years and older with type 2 diabetes who use basal insulin daily, according to a press release.